INTENSITY THERAPEUTICS, INC. shareholders approved Approval of any postponement or adjournment of 2026 annual meeting, if necessary at the 2026-06-16 meeting.
“For Against Abstain 939,304 126,814 13,376”
INTENSITY THERAPEUTICS, INC. — fact timeline
Source-grounded facts extracted from INTENSITY THERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INTENSITY THERAPEUTICS, INC. shareholders approved Approval of amendment to 2024 Employee Stock Purchase Plan to increase shares available by 25,000 at the 2026-06-16 meeting.
“For Against Abstain Broker Non-Votes 407,404 25,350 3,324 643,416”
INTENSITY THERAPEUTICS, INC. shareholders approved Approval of amendment to 2021 Stock Incentive Plan to increase shares available by 150,000 at the 2026-06-16 meeting.
“For Against Abstain Broker Non-Votes 363,563 69,252 3,263 643,416”
INTENSITY THERAPEUTICS, INC. shareholders approved Ratification of selection of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-16 meeting.
“For Against Abstain 1,024,971 4,852 49,671”
INTENSITY THERAPEUTICS, INC. shareholders approved Election of two Class III directors to hold office until the 2029 annual meeting at the 2026-06-16 meeting.
“Nominee For Withheld Broker Non-Votes Dr. Emer Leahy 416,613 19,465 643,416 Lewis H. Bender 422,149 13,929 643,416”
INTENSITY THERAPEUTICS, INC. reported the three months ended March 31, 2026 results: net income net loss was $2.4 million.
“31, 2025. This increase was partially offset by lower stock-based compensation and one-time expenses related to our reverse stock split in February 2026. Overall, net loss was $2.4 million for the three months ended March 31, 2026, compared to a net loss of $3.3 million for the three months ended March 31, 2025. As of March 31, 2026, cash and cash equivalents”
INTENSITY THERAPEUTICS, INC. reported financial results for the year ended December 31, 2025.
“On March 27, 2026, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2025.”
INTENSITY THERAPEUTICS, INC.: Filed amendment to certificate of incorporation to effect a 1-for-25 reverse stock split (effective 2026-02-13).
“On February 13, 2026, Intensity Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its amended and restated certificate of incorporation, as amended, to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-25 (the “Reverse Stock Split”).”
INTENSITY THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“December 4, 2025, the “Company received a second letter (the “December 2025 Nasdaq Letter”) from Nasdaq stating that the Company is eligible for an additional 180 calendar days, or until June 1, 2026, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Staff of the Nasdaq (the “Staff”) determined that the Company is eligible for the second 180 calendar day period, or until June 1, 2026, to regain compliance with the Rule based on the Staff’s determination that the Company must continue to meet the continued listing requirement”
INTENSITY THERAPEUTICS, INC.: Amended Section 2.7 of Bylaws to reduce stockholder meeting quorum requirement from majority to at least one-third of voting power entitled to vote, effective August 12, 2025 (effective 2025-08-12).
“On August 12, 2025, the Board of Directors of Intensity Therapeutics, Inc. (the “Company”), adopted an amendment (the “Amendment”) to the Amended and Restated Bylaws of the Company (the “Bylaws”). The changes to the Bylaws pursuant to the Amendment are effective as of August 12, 2025. The Amendment amends Section 2.7 of the Bylaws, dealing with a quorum at meetings of stockholders, to generally provide that a quorum is at least one-third of the voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy. Prior to effectiveness of the Amendment, a quorum is a majority of the voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy.”
INTENSITY THERAPEUTICS, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
“June 6, 2025, Intensity Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notice has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on The Nasdaq Capital Market under the symbol “INTS” at this time. In accordance with Nasdaq List”
INTENSITY THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 19, 2025, Intensity Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities o”
James Ahlers was removed as other_named_officer at INTENSITY THERAPEUTICS, INC..
“On May 21, 2024, the Board of Directors of Intensity Therapeutics, Inc. (the “Company”) resolved that Mr. James Ahlers (i) shall be removed as an officer of the Company pursuant to the Company’s bylaws”
Thomas I. H. Dubin was appointed as Class I director at INTENSITY THERAPEUTICS, INC..
“appointed Thomas I. H. Dubin to the Board as a Class I director.”
INTENSITY THERAPEUTICS, INC. entered into Collaboration Agreement with The Swiss Group for Cancer Research SAKK valued at funding in the amount of up to approximately $3.0 million (effective 2024-05-06).
“On May 6, 2024, Intensity Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with The Swiss Group for Cancer Research SAKK (“SAKK”).”
INTENSITY THERAPEUTICS, INC. reported the three months ended March 31, 2024 results: net income Net loss was $4.6 million.
“On May 9, 2024, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three months ended March 31, 2024.”
INTENSITY THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4), 5605(a)(2), 10A-3).
“April 18, 2024, the Company received a letter (the "Letter") from Nasdaq notifying the Company that, as a result of the resignation of Daniel Donovan from the Audit Committee, the Company is not in compliance with Nasdaq’s audit committee composition requirements as set forth in Nasdaq Listing Rule 5605. The Letter further provides that, pursuant to Nasdaq Listing Rule 5605(c)(4), the Company is entitled to a cure period to regain compliance with Nasdaq Listing Rule 5605, which cure period will expire the earlier of the Company's next annual stockholders' meeting or April 14, 2025; or if the n”
INTENSITY THERAPEUTICS, INC. reported financial results for year ended December 31, 2023.
“On March 14, 2024, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2023.”
John Wesolowski changed role as Chief Financial Officer at INTENSITY THERAPEUTICS, INC..
“With the appointment of Mr. Talamo as the Company’s new Chief Financial Officer, Mr. Wesolowski will no longer serve in this capacity but will continue on as the Company’s Principal Accounting Officer and Controller.”
Joseph Talamo was appointed as Chief Financial Officer at INTENSITY THERAPEUTICS, INC..
“On December 11, 2023, Intensity Therapeutics (the “Company”), appointed Joseph Talamo to serve as the Chief Financial Officer of the Company effective December 11, 2023.”
INTENSITY THERAPEUTICS, INC.: Board adopted second amended and restated bylaws effective immediately, enhancing procedural mechanics for shareholder nominations and making other updates (effective 2023-11-21).
“On November 21, 2023, the board of directors of Intensity Therapeutics, Inc. (the “Company”) adopted the second amended and restated bylaws (the “Second Amended and Restated Bylaws”), effective immediately.”
INTENSITY THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: net income Net Operating Loss for the second quarter ended June 30, 2023 was $1.2 million.
“Intensity Therapeutics, Inc. (the “ Company ”) released its financial results for the quarter ended June 30, 2023. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.”
INTENSITY THERAPEUTICS, INC.: Adopted amended and restated Bylaws effective upon closing of the Offering (effective 2023-07-05).
“In connection with the closing of the Offering, effective as of July 5, 2023, the Company adopted amended and restated bylaws (the “ Amended and Restated Bylaws ”).”
INTENSITY THERAPEUTICS, INC.: Filed Sixth Amended and Restated Certificate of Incorporation in connection with closing of the initial public offering (effective 2023-06-30).
“In connection with the closing of the Offering, on June 30, 2023, the Company filed its Sixth Amended and Restated Certificate of Incorporation (the “ Sixth Amended and Restated Charter ”).”
INTENSITY THERAPEUTICS, INC. entered into Underwriting Agreement with The Benchmark Company, LLC valued at Total gross proceeds of $19,500,000 from sale of 3,900,000 shares at $5.00 per share (effective 2023-06-29).
“On June 29, 2023, Intensity Therapeutics, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with The Benchmark Company, LLC, as representative of the underwriters named on Schedule 1 thereto (the “Representative ”) relating to the Company’s firm commitment underwritten initial public offering (the “ Offering ”) of common stock, par value $0.0001 per share (the “ Common Stock ”), which was registered under the Securities Act of 1933, as amended (the “ Securities Act ”) by the Company’s registration statement on Form S-1, as amended (File No. 333-260565) (the “ Registration Statement ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.